Thousands of patients are suing the companies behind GLP-1 weight loss drugs, alleging they caused blindness, loss of brain function and organ damage. Jonathan Orent, an attorney representing some of the plaintiffs, tells “Morning in America” that European warning labels also include information about the risk of blindness. He argues that drugmakers have failed to sufficiently inform doctors in the U.S. about the full risk-benefit profile, limiting physicians’ ability to discuss those risks with